PD-L1 overexpression

Immunotherapy has expanded therapeutic GTN, transforming refractory disease as a result of its immune responsiveness. Checkpoint inhibition not only achieves high remission rates but also offers fertility preservation and long-term survivorship. The future challenge lies in optimizing combination strategies, refining biomarkers, and ensuring equitable global access to these emerging treatments.

Clinical trials of Claudin 18.2-targeted therapies (e.g., Zolbetuximab) further expand personalized treatment options...Despite the abundance of research in this field, this paper prioritizes the analysis and discussion of prospective or high-quality retrospective studies that include explicit efficacy prediction endpoints (such as pCR, TRG, AUC) to ensure the reliability of the evidence presented. This review emphasizes that multi-omics integrated predictive models and the clinical translation of targeted therapies represent critical directions for future research, aiming to optimize the neoadjuvant treatment strategies for locally advanced gastric cancer.

P2, N=5, Active, not recruiting, University of Southern California | Trial completion date: Jul 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Dec 2026 | Terminated --> Active, not recruiting

Our findings demonstrate favorable long-term outcomes for patients with an MPR and identify IFNγ and PD-L1 as promising baseline biomarkers. ClinicalTrials.gov identifier: NCT02977052 .

Although dMMR was associated with initial treatment resistance, its unique immunogenicity was found to influence disease progression and subsequent treatment options. These findings suggested that MMR testing in LA-HNSCC patients had significant clinical value, not only aiding in the identification of patients who might benefit from subsequent immunotherapy but also potentially informing initial treatment strategies, such as the prospective exploration of combined immunotherapy approaches.

The landscape of first-line treatment for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations is rapidly evolving, currently dominated by pembrolizumab-based regimens. Secondly, cemiplimab displays consistent, robust efficacy in challenging-to-treat squamous histology, both as monotherapy for patients with high PD-L1 expression and in combination with chemotherapy for patients with PD-L1 < 50%. In conclusion, cemiplimab establishes a unique therapeutic niche for patients with squamous histology and ultra-high PD-L1 expression, likely driven by its distinct structural stability and reduced immunogenicity.

The strong association of KRAS mutations with high PD-L1 expression, irrespective of smoking history, highlights the interplay between genetic and immunological pathways in NSCLC. These findings support the routine implementation of broad molecular testing to guide precision oncology approaches in both adenocarcinoma and squamous cell carcinoma patients.

This method was applied to tumor transcriptomic data from the IMvigor210 cohort (n = 298), comprising mUC patients treated with atezolizumab...Our framework, which combines SHAP-based interpretable feature extraction with spectral clustering, revealed subclass-level heterogeneity in ICI response, highlighting biologically distinct immune subclasses. This approach may facilitate the development of subclass-specific therapeutic strategies.

Our findings demonstrate that MAP3K19 drives hypopharyngeal cancer progression by crippling DC activation, maturation, and function. MAP3K19 orchestrates DC dysfunction by phosphorylating and inactivating GSK3β, which simultaneously suppresses the NF-κB pathway and enhances PD-L1 protein stability. Targeting the MAP3K19/GSK3β axis may represent a novel therapeutic strategy to reverse immunosuppression in hypopharyngeal cancer.

These findings demonstrate that Roscovitine potentiates anti-PD-1 therapy by simultaneously suppressing immunosuppressive cell populations and amplifying effector immune responses. The dual modulation of PD-L1 expression and immune cell dynamics provides a strong rationale for the clinical evaluation of Roscovitine in combination with immune checkpoint blockade in NSCLC and potentially other solid tumors.

However, in IO non-exposed tumors, CTNNB1-high expression was associated with improved overall survival (HR = 0.97, 95% CI 0.96-0.98, p < 0.00001). In conclusion, our analysis indicates that expression of PD-L1, CTNNB1, and other molecular markers most associated with IO response in other gastrointestinal malignancies are not directly indicative of such responses in HCC.

These data support routine PD-L1 assessment and suggest that advanced age alone should not preclude consideration of immunotherapy. Findings may inform trial design and real-world treatment decision-making.